ChromaDex logo

ChromaDexNASDAQ: CDXC

Profile

Country:

United States

IPO:

25 June 2008

Next earnings report:

06 March 2025

Last dividends:

N/A

Next dividends:

N/A
$435.10 M
-2%vs. 3y high
44%vs. sector
-vs. 3y high
-vs. sector
-9%vs. 3y high
96%vs. sector
-30%vs. 3y high
93%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:59:59 GMT
$5.73+$1.61(+39.08%)

Dividend

No data over the past 3 years
$25.58 M$25.95 M
$25.58 M$1.88 M

Analysts recommendations

Institutional Ownership

CDXC Latest News

ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
seekingalpha.com01 November 2024 Sentiment: NEUTRAL

ChromaDex Corporation (NASDAQ:CDXC ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Ben Shamsian - IR Rob Fried - CEO Ozan Pamir - CFO Andrew Shao - SVP, Scientific & Regulatory Affairs Wesley Yu - VP, Finance Conference Call Participants Jeff Cohen - Ladenburg Thalmann & Co. Edward Marks - H.C. Wainwright Bill Dezellem - Tieton Capital Management Sean McGowan - ROTH MKM Partners J.P.

ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates
zacks.com31 October 2024 Sentiment: POSITIVE

ChromaDex (CDXC) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.01 per share a year ago.

ChromaDex Appoints Ozan Pamir as Chief Financial Officer
businesswire.com20 September 2024 Sentiment: POSITIVE

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CFO--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Ozan Pamir as Chief Financial Officer. Mr. Pamir will oversee all ChromaDex corporate finance matters, including accounting, strategic financial planning, and engaging with public markets through investor relations. Effective October 21, 2024, he will report directly to Rob Fried, CEO of ChromaDex and F.

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
businesswire.com23 August 2024 Sentiment: POSITIVE

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #BioScience--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Thursday, August 29, 2024, at 2:00 PM EDT. ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend this live event.

ChromaDex (CDXC) Reports Break-Even Earnings for Q2
zacks.com07 August 2024 Sentiment: POSITIVE

ChromaDex (CDXC) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.03 per share a year ago.

ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
businesswire.com22 July 2024 Sentiment: POSITIVE

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Carlos Lopez as Senior Vice President, General Counsel. Mr. Lopez will oversee the organization's legal function, including corporate governance, securities, intellectual property, and litigation. Effective today, July 22, 2024, he will report directly to Rob Fried, CEO of ChromaDex and Founder of Tru N.

Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
businesswire.com24 June 2024 Sentiment: POSITIVE

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research, shares results from a milestone phase II clinical study showcasing the promising effects of nicotinamide riboside (NR) supplementation for people with peripheral artery disease (PAD). This study was part of the ChromaDex External Research Program (CERP®), which donated ChromaDex's patented NR ingredient, Niagen®, the most efficient and high-quality NAD+ precurs.

ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
zacks.com10 June 2024 Sentiment: POSITIVE

ChromaDex (CDXC) rises 12% as the FDA grants the Orphan Drug Designation and the Rare Pediatric Disease Designation to its investigational candidate, NRC, to treat ataxia telangiectasia.

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
businesswire.com04 June 2024 Sentiment: POSITIVE

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, June 11, 2024, at 2:00pm PST. ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend this live event. The presentation.

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
Business Wire21 February 2024 Sentiment: NEGATIVE

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex.

What type of business is ChromaDex?

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

What sector is ChromaDex in?

ChromaDex is in the Consumer Defensive sector

What industry is ChromaDex in?

ChromaDex is in the Packaged Foods industry

What country is ChromaDex from?

ChromaDex is headquartered in United States

When did ChromaDex go public?

ChromaDex initial public offering (IPO) was on 25 June 2008

What is ChromaDex website?

https://www.chromadex.com

Is ChromaDex in the S&P 500?

No, ChromaDex is not included in the S&P 500 index

Is ChromaDex in the NASDAQ 100?

No, ChromaDex is not included in the NASDAQ 100 index

Is ChromaDex in the Dow Jones?

No, ChromaDex is not included in the Dow Jones index

When was ChromaDex the previous earnings report?

No data

When does ChromaDex earnings report?

The next expected earnings date for ChromaDex is 06 March 2025